Effectiveness of treatment for MDR TB in children and adolescents Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007
Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges Source: Eur Respir J 2016; 48: 938-943 Year: 2016
ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use Source: Eur Respir J 2014; 44: 811-815 Year: 2014
Bedaquiline in the treatment of multidrug-resistant tuberculosis: a subanalysis in Korean population Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
Preventive chemotherapy effectiveness in children and adolescents, contacting TB patients with DR TB strains Source: Eur Respir J 2006; 28: Suppl. 50, 536s Year: 2006
Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea Source: Eur Respir J, 57 (3) 2003026; 10.1183/13993003.03026-2020 Year: 2021
HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Patients over 35 years experience more side-effects during latent TB treatment: Experience from an urban hospital with a high incidence of Tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Incidence of tuberculosis among anti-TNF users in patients with previous history of tuberculosis Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013
Predictors of defaulting from treatment among patients with tuberculosis Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid Source: Eur Respir J 2015; 45: 1498-1501 Year: 2015
Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review Source: Eur Respir J, 52 (1) 1800395; 10.1183/13993003.00395-2018 Year: 2018
Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review Source: Eur Respir J, 53 (1) 1801030; 10.1183/13993003.01030-2018 Year: 2019
A two-year post-treatment follow-up of multi-drug resistant tuberculosis cases who completed a programmatic MDR-TB management at the lung center of the Philippines – a preliminary report Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis Year: 2009